lncTIMP3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis

Taxi Wumiti,Lining Wang,Bin Xu,Yong Ma,Yihua Zhu,Xinchen Zuo,Weiqing Qian,Xudong Chu,Haitao Sun
DOI: https://doi.org/10.1007/s11033-024-09652-w
IF: 2.7422
2024-06-02
Molecular Biology Reports
Abstract:Promoting the balance between bone formation and bone resorption is the main therapeutic goal for postmenopausal osteoporosis (PMOP), and bone marrow mesenchymal stem cells (BMSCs) osteogenic differentiation plays an important regulatory role in this process. Recently, several long non-coding RNAs (lncRNAs) have been reported to play an important regulatory role in the occurrence and development of OP and participates in a variety of physiological and pathological processes. However, the role of lncRNA tissue inhibitor of metalloproteinases 3 (lncTIMP3) remains to be investigated.
biochemistry & molecular biology
What problem does this paper attempt to address?